Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P01189 (
beta-endorphin
)
21,003
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The synthesis and purification of several analogues of the melanotropins with amino acid substitutions at the tyrosine-2 and methionine-4(7) positions are reported. The compounds synthesized included [4-norleucine]-
alpha-MSH
, [7-norleucine]-beta p-MSH, [2-3',5'-diiodotyrosine]-
alpha-MSH
, [2-D-tyrosine]-
alpha-MSH
, and [
2-phenylalanine
,4-norleucine]-
alpha-MSH
. The biological activities of these derivatives were measured and compared on normal melanocytes (frog skins) and on transformed melanocytes (mouse melanoma adenylate cyclase), over the entire dose-response range. All compounds tested were full agonists in both assay systems but varied considerably in potency. The relative potencies in the frog skin assay (
alpha-MSH
= 1.0) were as follows: [Nle7]-beta p-MSH (5.2) > [Nle4]-
alpha-MSH
(2.3) >
alpha-MSH
(1.0) > [Phe2,Nle4]-
alpha-MSH
(0.80) > beta p-MSH (0.55) > [I2-Tyr2]-
alpha-MSH
(0.12) > [D-Tyr2]-
alpha-MSH
(0.04). The relative potencies in the melanoma adenylate cyclase system were [Nle7]-beta p-MSH (4.2) > beta p-MSH (2.2) > [Nle4]-
alpha-MSH
(2.0) >
alpha-MSH
(1.0) approximately equal to [Phe2,Nle4]-
alpha-MSH
(0.9) > [I2-Tyr2]-
alpha-MSH
(0.40) > [D-Tyr2]-
alpha-MSH
(0.20). There appears to be some differences in structural specificity at the melanotropin receptors of the two cell systems.
...
PMID:Synthesis and structure-function studies of melanocyte stimulating hormone analogues modified in the 2 and 4(7) positions: comparison of activities on frog skin melanophores and melanoma adenylate cyclase. 745 98